FinWiki
日EN中

Medical / cancer insurance product economics in Japan

置信度: 大致可信 更新 2026-05-25 复核期限 2026-11-25 出处 7 机器翻译 原文（日）
#insurance#life#medical#cancer#aflac#aia
本页目录

TL;DR

Medical (医療保険) and cancer (がん保険) insurance are the dominant individual-protection product lines in the Japanese life-insurance market in number of contracts and in retail visibility, sitting on top of (not as a substitute for) the universal public health-insurance system run under the Ministry of Health, Labour and Welfare (MHLW / 厚生労働省). The competitive structure is dominated by a small number of specialist-positioned carriers — Aflac 人寿保险（Aflac Japan） holds a structurally dominant share of the cancer-insurance line (commonly reported around the ~70% bracket of individual cancer-policy in-force), AIA Group is a major foreign-life writer of medical / protection, the non-life big three subsidiaries Tokio Marine & Nichido Life “Anshin”, Sompo Himawari Life, and the MS&AD Aioi Nissay Dowa Life / Mitsui Sumitomo Aioi Life vehicles compete with bundled / rider-led offerings, and the life big-four mutuals offer medical / cancer protection primarily as riders on whole-life or term-life base contracts. The economics are characterized by short-tail morbidity-driven loss ratios (different from rate-sensitive savings products), heavy distribution-channel cost (commission share is the largest single line in product economics), agency / bancassurance / direct channel substitution dynamics, and product-mix interaction with the internet life insurance business model for simple yen-term-style medical covers.

Wiki route

This page sits under insurance INDEX and is the product-economics counterpart to the life insurance channel mix, the Japan life big four (which sell medical / cancer mainly as riders on base policies), foreign-life-affiliate positioning (which is the primary frame for understanding Aflac and AIA), and the agency / brokerage Japan landscape (the dominant non-bank distribution channel for these products). Read it together with the internet life insurance business model for the direct-channel contrast and bancassurance economics Japan for the bank-channel comparative. The entity anchors include Aflac Japan, AIA Life Japan, Tokio Marine & Nichido Life (“Anshin Life”), Sompo Himawari Life, and MetLife Japan and Prudential Japan for the broader foreign-affiliate set.

Why these products are a separate product economics

A whole-life or single-premium savings policy is a long-duration, rate-sensitive product whose economics turn on ALM, hedge-ratio, and reserve dynamics (see the Japan life ALM overview). A medical / cancer policy is a different product class:

  • Short-tail and morbidity-driven. Claims drive on observed morbidity (hospitalization days, surgery counts, cancer diagnosis frequency) rather than on mortality or interest rates. Loss-ratio is the dominant cost line, not reserve build.
  • No major savings component. Most medical and cancer products are pure-protection; no large policy-reserve accumulation, no surrender-value optimization problem comparable to whole-life or annuity.
  • Premium structure is level or short. Many products price as level monthly premium for whole-life morbidity protection; some price as renewable term medical; cancer products often sell as level-premium whole-life cancer cover.
  • Layered on public health insurance. All Japan residents are covered by either employee health insurance (健康保険), national health insurance (国民健康保険), or the late-elderly system (後期高齢者医療制度) administered under MHLW frameworks. Private medical / cancer products pay benefits in addition to the public system rather than instead of it: hospitalization daily benefits, surgery one-time benefits, cancer-diagnosis lump-sum, outpatient cancer-treatment monthly benefits.
  • Distribution cost is the dominant economic line. Acquisition commission to agencies, banks, or sales reps is the largest variable cost; advertising spend matters for direct / internet plays. Pricing-margin compression therefore happens primarily through channel-mix, not through investment-income optimization.

Competitive map

Carrier / groupProduct positioningChannel mixNotes
[[life-insurers/aflac-japanAflac Japan]]Cancer dominant; medical strong; “AFLAC duck” brandDedicated agency network + bancassurance + tied + corporate; long postal-channel tie-up history with Japan Post Co.
[[life-insurers/aia-life-japanAIA Life Japan]]Medical / protection / wellness; whole-life ridersTied + agency; “AIA Vitality” overlay
[[life-insurers/tokio-marine-nichido-lifeTokio Marine & Nichido Life (“Anshin Life”)]]Medical + protection + bundled with non-life via groupGroup agency, bancassurance, direct (via [[non-life-insurers/tokio-marine-direct
[[life-insurers/sompo-himawari-lifeSompo Himawari Life]]Medical / cancer / nursing; wellness-linkedGroup agency, bancassurance
MS&AD life vehicles (Mitsui Sumitomo Aioi Life, Mitsui Sumitomo Primary Life)Medical riders + savings + bancassuranceGroup agency, bancassurance, primary-life for bancassuranceNon-life big-three life subsidiaries inside [[non-life-insurers/ms-ad
[[insurance/japan-life-insurance-big-fourLife big-four mutuals + Dai-ichi HD]]Medical / cancer riders attached to whole-life / term baseTied sales force
Internet direct ([[life-insurers/lifenetLifenet]] etc.)Simple yen medical / term / cancer coverInternet direct
[[life-insurers/metlife-japanMetLife Japan]], [[life-insurers/prudential-japanPrudential Japan]]Protection / whole-life / medical mix

The Aflac cancer share is the structural anomaly of the Japan medical / cancer market: a single foreign-affiliate carrier holds a share of one product line that no comparable carrier holds in any other Japan life-insurance product line. The history runs back to Aflac’s 1974 entry as the first foreign insurer to operate independently in Japan and the first carrier with a specialized cancer-product license, with subsequent market lockup through agency, postal, and bancassurance distribution.

Product economics components

For a representative individual medical / cancer policy, the economic components are:

  • Gross written premium — level monthly premium typically; some products price as single-premium or limited-pay.
  • Claims (loss) cost — hospitalization day benefits, surgery one-time benefits, cancer-diagnosis lump-sum, outpatient cancer-treatment monthly benefits, advanced-treatment (先進医療) cost-reimbursement riders. Loss ratio is typically the largest line.
  • Acquisition commission — to agencies (first-year and renewal), bank channels (front-loaded), tied sales (salary + production bonus), or marketing spend (direct / internet). Often the single largest distribution-cost line.
  • Maintenance expense — policy administration, claims handling, customer-service center costs.
  • Reserve change — for level-premium whole-life morbidity products, a meaningful reserve build sits between gross premium and current-year claims; for renewable term, reserve is small.
  • Investment income — modest contribution given short duration of held reserves; not the primary economic driver.
  • Underwriting margin — what remains; sensitive to morbidity assumption, expense ratio, and persistency.

The morbidity-assumption sensitivity is the structural underwriting risk: cancer-incidence trends, hospitalization-pattern shifts (shorter hospital stays driven by outpatient treatment), medical-technology shifts (cancer treatment moving outpatient, hospitalization days falling, but outpatient cancer-treatment riders growing), and population aging all shift the underlying loss curve.

Channel-cost interaction

The largest single product-economics question is which channel acquires the policy and at what commission share:

  • Agency channel (insurance shop / hokenshop / agency networks) — first-year commission can run a meaningful fraction of first-year premium; renewal commission continues for several years. The “insurance shop” / multi-carrier comparison channel (Hoken-no-madoguchi, Hoken-mammoth, hoken-shop chains) is a major medical / cancer acquisition channel.
  • Bancassurance — see bancassurance economics Japan; product fit is variable, with medical / cancer being a smaller share than annuity / single-premium savings.
  • Tied sales force — the dominant channel for life big-four medical / cancer riders attached to base policies.
  • Postal channel — historical Aflac-Japan Post Co. partnership for cancer products through the post-office branch network; the partnership has been a major Aflac distribution surface for decades.
  • Internet direct — see the internet life insurance business model; the channel applies pricing pressure on simple medical / term-cancer products but has not displaced the agency / tied channels for the broader product set.
  • Corporate channel — group-paid medical / cancer cover via employer-paid or salary-deduction schemes; relatively small share compared to individual.

A product designed for one channel does not always sell well in another. Cancer single-illness products with diagnosis-lump-sum benefits suit agency and post-office sales (concrete benefit story); medical riders suit tied sales (bundled into a relationship-driven base-policy sale); simple medical cover suits internet direct (low underwriting friction).

Public-system overlay

All Japan residents are covered by public health insurance under MHLW frameworks:

  • Employee health insurance (健康保険 / 全国健康保険協会 / 各健保組合) — for employees and dependents; typically 30% out-of-pocket cost-share on covered medical expenses with high-cost medical-expense cap (高額療養費制度).
  • National health insurance (国民健康保険) — for self-employed and non-employees; same general structure.
  • Late-elderly medical system (後期高齢者医療制度) — for residents 75+, with different cost-share.
  • High-cost medical expense system (高額療養費制度) — caps out-of-pocket monthly cost based on income tier; structurally limits the residual cost that private medical insurance is asked to cover.

Private medical / cancer products are sold on top of these public-system benefits. The advanced-treatment (先進医療) rider is a particular product-design response — public health insurance does not cover specific advanced treatments (proton therapy, heavy-ion therapy, etc.) and a low-cost rider can buy meaningful protection against those one-off catastrophic costs. Cancer-diagnosis lump-sum is similarly designed to cover income-loss and non-medical costs (transportation, family caregiving) that public health insurance does not address.

Decision use

Use this page when:

  • Reading any Japan life-insurance carrier’s individual-product mix and trying to size the medical / cancer line relative to whole-life, term, and annuity.
  • Modelling Aflac Japan’s specific competitive position and the durability of its cancer-share franchise.
  • Analysing the agency / hoken-shop channel and its product-mix profile (medical / cancer concentration).
  • Pricing-power comparison: the internet-direct channel applies pressure on simple medical products but agency commission economics still dominate the standard product set.
  • Tracking the medical / cancer rider attachment rates on whole-life / term base policies at the life big-four mutuals.
  • Cross-referencing public-system change (MHLW cost-share / 高額療養費 adjustment) into private-product demand.

Boundary cases / caveats

  • Cancer share is estimated. The ~70% Aflac cancer-share figure is commonly cited in trade press and Aflac IR; the precise share depends on counting basis (in-force contracts vs new contracts vs premium).
  • Medical / cancer is not standalone for all carriers. Some sell standalone single-illness cancer; others sell only as riders. Comparing “cancer share” across carriers requires same counting basis.
  • Public-system change affects design. MHLW cost-share rule changes, 高額療養費 cap changes, or coverage-list changes can shift private-product demand.
  • Outpatient-treatment shift. Cancer treatment has shifted toward outpatient; products designed around hospitalization-day benefits face declining utility on that benefit line and growing utility on outpatient-treatment riders.
  • Loss-ratio reporting. Carrier disclosure formats vary; cross-carrier loss-ratio comparison requires care.
  • Channel-economics figures are not standard public disclosure. Commission shares to agencies, banks, and other channels are not always publicly reported; trade-press figures are indicative.
  • Foreign-affiliate competitive dynamics. Aflac and AIA both compete with each other and with the non-life big-three life subsidiaries and life big-four; the foreign-affiliate frame in positioning is the broader context.

Sources

  • Aflac Inc.: investor materials and Aflac Japan disclosure.
  • Aflac Japan: corporate site and product disclosure.
  • AIA Group: Japan operating disclosure.
  • Tokio Marine & Nichido Life Insurance (“Anshin Life”): corporate site.
  • Sompo Himawari Life: corporate site.
  • MHLW: public health-insurance / 高額療養費 system documentation.
  • Life Insurance Association of Japan: industry statistics.